Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: Click here for what to expect at ChristianaCare during COVID-19

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: Click here for what to expect at ChristianaCare during COVID-19

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

About Cancer Clinical Trials

When you join a cancer research study, commonly referred to as a clinical trial, you benefit from some of the latest techniques and therapeutic advances in the fight against cancer. At the same time, you are helping to improve our knowledge in ways that will help people with cancer to live longer and enjoy a better quality of life. Other benefits of clinical trials include:

  • The very latest medicines available to treat your cancer.
  • Frequent and thorough medical exams.
  • The latest information to help you better understand your condition.
  • The guidance you need to improve your health.
  • Support and counseling from doctors and nurses on the hospital’s research staff.

There are four types of cancer clinical trials:

  • Prevention trials test new drugs or techniques designed to prevent the development of cancer in people at risk.
  • Control trials test treatments for the symptoms and side effects caused by cancer and examine quality-of-life issues.
  • CCDR trials are focused on patient, provider and organizational level influences on cancer outcomes.
  • Treatment trials test the effectiveness of new cancer therapies and drugs.

Along with our partners at the Cawley Center for Translational Cancer Research and the University of Delaware Department of Biological Sciences, ChristianaCare’s Cancer Research Program conducts all four types of clinical trials. If you are a patient at the Helen F. Graham Cancer Center & Research Institute, your cancer care-management team will discuss clinical trials with you. But you may also contact the Cancer Research Program directly to learn more about clinical trials and find out which ones you may be eligible for. For immediate, real-time access to all National Cancer Institute approved cancer trials that are open at ChristianaCare, visit Clinicaltrials.gov.

Researching the cancer-fighting drugs of tomorrow

Treatment trials that test new cancer drugs proceed through several stages before successful new drugs can be made available to the general population. These drugs are first tested in laboratory and animal studies. Medicines that proceed to be tested in people must follow rigid guidelines set by the U.S. Food and Drug Administration.

Research studies to test new drugs in people are categorized in four phases:

  • Phase I clinical trials involve a small group of volunteers. They are designed to test a drug’s safety and to determine how it works in the human body.
  • Phase II studies test the effectiveness of the drug on a few hundred, closely monitored volunteer patients who have the disease the drug is designed to treat.
  • Phase III trials involve several thousand volunteer patients who are closely monitored in clinics and hospitals to confirm the effectiveness and adverse effects of the drug in treating their illness compared to standard therapy.
  • Phase IV trials are sometimes required by the FDA to evaluate any long-term effects of a drug or treatment.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.